Get the Stockscreener App
0.4475
1.64%
0.0072
After Hours:
.45
0.0025
+0.56%
Scilex Holding Company stock is traded at $0.4475, with a volume of 977.32K.
It is up +1.64% in the last 24 hours and down -20.74% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$0.4403
Open:
$0.442
24h Volume:
977.32K
Relative Volume:
0.47
Market Cap:
$71.72M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-0.7443
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
-11.82%
1M Performance:
-20.74%
6M Performance:
-77.17%
1Y Performance:
-65.58%
1-Day Range:
$0.43
$0.45
1-Week Range:
$0.43
$0.5399
52-Week Range:
$0.43
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
0.4475 | 71.72M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
Scilex Holding Company Stock (SCLX) Latest News
Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa
Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks
Palo Alto pharmaceutical company secures $17M - Silicon Valley Business Journal
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Scilex Holding Company closes registered direct offering - Medical Buyer
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times
Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks
Scilex secures $17 million in stock and warrant sale - Investing.com
Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times
Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks
Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times
SCLX: Deal Brings Huge Potential - Research Tree
Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria
Scilex Holding agrees to share sale to meet debt obligations - Investing.com
Scilex Announces Joint Venture for CNS Compound Development - TipRanks
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times
NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire
NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - The Manila Times
Scilex and IPMC announce joint venture for obesity drug By Investing.com - Investing.com UK
Scilex Holding Company Enters into a Binding Term Sheet for - GlobeNewswire
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat
Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa
Scilex receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Scilex Holding Co reaches agreement to waive default penalties - Investing.com
Scilex receives Nasdaq non-compliance notice - Investing.com India
Scilex Holding Company Announces Receipt of Notice from Nasdaq - The Manila Times
Scilex Holding Company Announces Receipt of Notice from Nasdaq - GlobeNewswire Inc.
Sciatica Market Report 2032, DelveInsight | Sciatica Therapies & Companies, Clinical trials, Sciatica Treatment | Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kol - The Globe and Mail
Open Text Corp (OTEX-Q) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 1419, 2024 - The Manila Times
Scilex Holding Company Announces Presentation of Data at - GlobeNewswire
Scilex Holding Company Announces Presentation of Data at the 2024 American College of ... - The Bakersfield Californian
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 - Yahoo Finance
Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - Simply Wall St
SCLX stock touches 52-week low at $0.73 amid market challenges - Investing.com
Denali Capital (DECA) Secures Extension for Merger Deal, Issues $180K Note to Scilex - StockTitan
Scilex shares face delisting risk on Nasdaq - Investing.com India
Scilex Holding Plans Merger to Boost Semnur Value - TipRanks
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Pre - The Manila Times
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scilex Holding Company Stock (SCLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
| Followwill Dorman | Director |
Jun 26 '24 |
Option Exercise |
1.37 |
1,000 |
1,370 |
1,300 |
1.83%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):